Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4766 | 1656 | 44.9 | 90% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
876 | 10798 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//ABCG2 |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | P GLYCOPROTEIN | Author keyword | 67 | 11% | 35% | 574 |
2 | C3435T POLYMORPHISM | Author keyword | 61 | 95% | 1% | 20 |
3 | ABCB1 | Author keyword | 53 | 28% | 10% | 162 |
4 | MDR1 | Author keyword | 39 | 21% | 10% | 166 |
5 | TARIQUIDAR | Author keyword | 33 | 71% | 2% | 27 |
6 | C3435T | Author keyword | 29 | 88% | 1% | 14 |
7 | R C 11VERAPAMIL | Author keyword | 29 | 88% | 1% | 14 |
8 | PHARMACORESISTANCE | Author keyword | 25 | 35% | 3% | 57 |
9 | PHARMACOL TOXICOL PHARM | Address | 18 | 18% | 6% | 95 |
10 | C 11VERAPAMIL | Author keyword | 17 | 100% | 0% | 8 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | P GLYCOPROTEIN | 67 | 11% | 35% | 574 | Search P+GLYCOPROTEIN | Search P+GLYCOPROTEIN |
2 | C3435T POLYMORPHISM | 61 | 95% | 1% | 20 | Search C3435T+POLYMORPHISM | Search C3435T+POLYMORPHISM |
3 | ABCB1 | 53 | 28% | 10% | 162 | Search ABCB1 | Search ABCB1 |
4 | MDR1 | 39 | 21% | 10% | 166 | Search MDR1 | Search MDR1 |
5 | TARIQUIDAR | 33 | 71% | 2% | 27 | Search TARIQUIDAR | Search TARIQUIDAR |
6 | C3435T | 29 | 88% | 1% | 14 | Search C3435T | Search C3435T |
7 | R C 11VERAPAMIL | 29 | 88% | 1% | 14 | Search R+C+11VERAPAMIL | Search R+C+11VERAPAMIL |
8 | PHARMACORESISTANCE | 25 | 35% | 3% | 57 | Search PHARMACORESISTANCE | Search PHARMACORESISTANCE |
9 | C 11VERAPAMIL | 17 | 100% | 0% | 8 | Search C+11VERAPAMIL | Search C+11VERAPAMIL |
10 | ABCB1 POLYMORPHISM | 15 | 82% | 1% | 9 | Search ABCB1+POLYMORPHISM | Search ABCB1+POLYMORPHISM |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | C3435T POLYMORPHISM | 117 | 69% | 6% | 100 |
2 | C3435T | 54 | 72% | 3% | 43 |
3 | MULTIDRUG RESISTANCE GENE | 54 | 19% | 15% | 255 |
4 | PHARMACORESISTANCE | 48 | 70% | 2% | 40 |
5 | MULTIDRUG RESISTANT EPILEPSY | 42 | 94% | 1% | 15 |
6 | MDR1 GENE | 38 | 21% | 9% | 157 |
7 | MEDICALLY INTRACTABLE EPILEPSY | 37 | 42% | 4% | 69 |
8 | DRUG EFFLUX TRANSPORTERS | 34 | 49% | 3% | 51 |
9 | P GLYCOPROTEIN EXPRESSION | 33 | 14% | 13% | 216 |
10 | C3435T MUTATION | 33 | 67% | 2% | 29 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Regulation of ABC Transporters at the Blood-Brain Barrier | 2015 | 1 | 65 | 66% |
Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier | 2010 | 121 | 73 | 52% |
Why Clinical Modulation of Efflux Transport at the Human Blood-Brain Barrier Is Unlikely: The ITC Evidence-Based Position | 2013 | 39 | 68 | 31% |
The transport of antiepileptic drugs by P-glycoprotein | 2012 | 31 | 122 | 66% |
Drug resistance in brain diseases and the role of drug efflux transporters | 2005 | 376 | 129 | 51% |
Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance | 2004 | 545 | 137 | 39% |
Using Positron Emission Tomography to Study Transporter-Mediated Drug-Drug Interactions in Tissues | 2014 | 7 | 64 | 45% |
Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2) | 2012 | 41 | 238 | 43% |
ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis | 2010 | 39 | 38 | 79% |
ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies | 2013 | 8 | 22 | 82% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PHARMACOL TOXICOL PHARM | 18 | 18% | 5.7% | 95 |
2 | MOL BIOL PHARMACOGENOM | 5 | 63% | 0.3% | 5 |
3 | PROBE SECTINAGE KU | 3 | 100% | 0.2% | 3 |
4 | MEMBRANE TRANSPORT DRUG TARGETING | 3 | 20% | 0.7% | 12 |
5 | MOL PROBE | 2 | 44% | 0.2% | 4 |
6 | CLIN NEUROSURG EPILEPSY SURG | 2 | 67% | 0.1% | 2 |
7 | PHARMACEUT BIOCHEM MOL DIAGNOST | 2 | 67% | 0.1% | 2 |
8 | UNITE NEURO PHARMACO NUTR | 2 | 67% | 0.1% | 2 |
9 | NEUROPSYCHOPHARMACOL ADDICT CNRS UMR 8206 | 2 | 50% | 0.2% | 3 |
10 | BIOMED SYST HLTH ENVIRONM | 2 | 43% | 0.2% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000150931 | ABCG2//BCRP//BREAST CANCER RESISTANCE PROTEIN |
2 | 0.0000125210 | RHEUMATOLOTA KU//MDR I//DANINI HOSP |
3 | 0.0000113970 | CYP3A5//TACROLIMUS//CYTOCHROME P450 3A5 |
4 | 0.0000111178 | P GLYCOPROTEIN//MULTIDRUG RESISTANCE//PSC 833 |
5 | 0.0000104445 | MRP1//MULTIDRUG RESISTANCE ASSOCIATED PROTEIN//DUBIN JOHNSON SYNDROME |
6 | 0.0000083939 | HUMAN PLACENTAL PERFUSION//H 3DIGOXIN//PLACENTAL TRANSPORTERS |
7 | 0.0000083565 | BBB//TRANSENDOTHELIAL ELECTRICAL RESISTANCE//PHYSIOPATHOL BARRIERE HEMATO ENCEPHAL |
8 | 0.0000080853 | CACO 2//SINGLE PASS INTESTINAL PERFUSION//INTESTINAL PERFUSION |
9 | 0.0000079003 | INNER BLOOD RETINAL BARRIER//RETINAL CAPILLARY ENDOTHELIAL CELLS//DRUG DISPOSIT PHARMACOKINET |
10 | 0.0000069389 | MAJOR VAULT PROTEIN//LUNG RESISTANCE RELATED PROTEIN//VPARP |